<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126407</url>
  </required_header>
  <id_info>
    <org_study_id>CCSURA003229</org_study_id>
    <secondary_id>CCSURA003229</secondary_id>
    <nct_id>NCT05126407</nct_id>
  </id_info>
  <brief_title>A Study of Olynth Saline/Ectomed Nasal Drops/Spray Based Upon Previous Usage</brief_title>
  <official_title>A Non-Interventional Clinical Study to Assess the Risk and Performance Aspects of Olynth Saline/Ectomed Nasal Drops/Spray Based Upon Previous Usage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Consumer Inc. (J&amp;JCI)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Consumer and Personal Products Worldwide</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to proactively collect customer feedback on the performance&#xD;
      aspects and risk factors of Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 9, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Participant Feedback on the Performance Aspects of Olynth Nasal Saline Drops</measure>
    <time_frame>Up to 1 month and 14 days</time_frame>
    <description>Participant feedback on the performance aspects of Olynth Nasal Saline Drops will be assessed via electronic survey.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Feedback on the Performance Aspects of Olynth Nasal Saline Spray</measure>
    <time_frame>Up to 1 month and 14 days</time_frame>
    <description>Participant feedback on the performance aspects of Olynth Nasal Saline Spray will be assessed via electronic survey.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Feedback on the Performance Aspects of Olynth Ectomed Nasal Spray</measure>
    <time_frame>Up to 1 month and 14 days</time_frame>
    <description>Participant feedback on the performance aspects of Olynth Ectomed Nasal Spray will be assessed via electronic survey.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 1 month and 14 days</time_frame>
    <description>An AE is any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in participants, users or other persons, whether or not related to the investigational device.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Common Cold</condition>
  <condition>Sinusitis</condition>
  <condition>Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray</arm_group_label>
    <description>Participants who have personally used or administered the Olynth Nasal Saline Drops/Spray and Olynth Ectomed Nasal Spray to a child at least once within the past 6 months will provide feedback via electronic survey on the prior use of the Drop/Spray.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who has personally used or administered the Olynth Nasal Saline Drops/Spray&#xD;
        and Olynth Ectomed Nasal Spray to a child will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older who has personally used or administered the nasal drops/spray&#xD;
             to a child&#xD;
&#xD;
          -  Has personally used or administered to a child, the Nasal Drops/Spray at least once&#xD;
             within the past 6 months&#xD;
&#xD;
          -  Able to read, write, speak, and understand German&#xD;
&#xD;
          -  Has internet access to complete an on-line survey&#xD;
&#xD;
          -  Intends to complete the survey&#xD;
&#xD;
          -  Individual has signed the informed consent document (ICD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Is an employee/contractor or immediate family member of the principal investigator (PI),&#xD;
        Schlesinger group, product perceptions limited (PPL) Insights or sponsor of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akash Pandhare, MD. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johnson &amp; Johnson Consumer Inc. (J&amp;JCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Holdt</last_name>
    <phone>0049-89-231810-100</phone>
    <email>Christian.Holdt@SchlesingerGroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Schlesinger Group</name>
      <address>
        <city>Berlin</city>
        <zip>D-10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Spector SL, Toshener D, Gay I, Rosenman E. Beneficial effects of propylene and polyethylene glycol and saline in the treatment of perennial rhinitis. Clin Allergy. 1982 Mar;12(2):187-96.</citation>
    <PMID>7074822</PMID>
  </reference>
  <reference>
    <citation>Chirico G, Quartarone G, Mallefet P. Nasal congestion in infants and children: a literature review on efficacy and safety of non-pharmacological treatments. Minerva Pediatr. 2014 Dec;66(6):549-57. Review.</citation>
    <PMID>25336097</PMID>
  </reference>
  <reference>
    <citation>Eichel A, Wittig J, Shah-Hosseini K, Mösges R. A prospective, controlled study of SNS01 (ectoine nasal spray) compared to BNO-101 (phytotherapeutic dragées) in patients with acute rhinosinusitis. Curr Med Res Opin. 2013 Jul;29(7):739-46. doi: 10.1185/03007995.2013.800474. Epub 2013 May 14.</citation>
    <PMID>23621514</PMID>
  </reference>
  <reference>
    <citation>Köksal T, Çizmeci MN, Bozkaya D, Kanburoğlu MK, Şahin Ş, Taş T, Yüksel ÇN, Tatli MM. Comparison between the use of saline and seawater for nasal obstruction in children under 2 years of age with acute upper respiratory infection. Turk J Med Sci. 2016 Jun 23;46(4):1004-13. doi: 10.3906/sag-1507-18.</citation>
    <PMID>27513397</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

